Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic ...

Bylvay (odevixibat) – which Ipsen acquired when it took over US biotech Albireo in a $952 million deal in 2023 – was being ...

Against the advice of FDA staff scientists, an advisory committee has narrowly voted in support of looser restrictions on ...

The FDA has named Dexcom as the first medical device manufacturer that will take part in a pilot programme that could make it ...

After a delay of several years, people living with multiple sclerosis in England will finally be able to get NHS access to ...

China has become the first country to approve Takeda's first-in-class orexin agonist, oveporexton, for the sleep disorder ...

Armed with new pivotal trial results, Eli Lilly plans to file for approval of its keenly anticipated new weight-loss therapy, ...

In transfusion medicine, “wrong blood in tube” is not simply a paperwork issue: a misidentified blood group can lead to a ...

GSK has won FDA approval for Jideytro, a drug at the heart of its $10.6 billion acquisition of Nuvalent earlier this year – ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

Life sciences equipment and consumable manufacturer Repligen has reached a deal to buy cell therapy specialist BioLife ...

In the phase 3 MonumenTAL-6 trial, Tecvayli (teclistamab) and Talvey (talquetamab) cut the risk of disease progression or death by 89% compared to standard-of-care combinations used as second- to ...